Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

$118.31

-4.56 (-3.71%)

(As of 04/15/2024 ET)

Sarepta Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$158.38
33.86% Upside

High Forecast	$224.00
Average Forecast	$158.38
Low Forecast	$109.00

Type	Current Forecast 4/16/23 to 4/15/24	1 Month Ago 3/17/23 to 3/16/24	3 Months Ago 1/16/23 to 1/16/24	1 Year Ago 4/16/22 to 4/16/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$158.38	$159.35	$152.45	$166.89
Predicted Upside	33.86% Upside	30.06% Upside	39.21% Upside	24.75% Upside

Get Sarepta Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SRPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics Stock vs. The Competition

Type	Sarepta Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.68	2.48
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	33.86% Upside	882.04% Upside	11.23% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
3/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$164.00 ➝ $167.00	+32.58%
2/29/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$128.00	-2.54%
2/29/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$151.00 ➝ $157.00	+20.09%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$224.00	+71.29%
2/29/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$160.00 ➝ $172.00	+31.43%
2/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$141.00 ➝ $185.00	+34.55%
Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/29/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$169.00 ➝ $166.00	+20.73%
2/20/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	In-Line ➝ In-Line	$108.00 ➝ $138.00	+2.32%
2/14/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$130.00 ➝ $145.00	+17.55%
1/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$170.00	+42.75%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$109.00	+24.27%
10/31/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$211.00 ➝ $115.00	+70.85%
10/31/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/31/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$183.00 ➝ $146.00	+35.62%
6/23/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$176.00 ➝ $186.00	+50.10%
5/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$151.00 ➝ $141.00	+7.34%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00	+50.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:47 AM ET.

SRPT Price Target - Frequently Asked Questions

What is Sarepta Therapeutics's consensus rating and price target?: According to the issued ratings of 15 analysts in the last year, the consensus rating for Sarepta Therapeutics stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for SRPT. The average twelve-month price prediction for Sarepta Therapeutics is $158.38 with a high price target of $224.00 and a low price target of $109.00. Learn more on SRPT's analyst rating history.
Do Wall Street analysts like Sarepta Therapeutics more than its competitors?: Analysts like Sarepta Therapeutics more than other Medical companies. The consensus rating score for Sarepta Therapeutics is 2.80 while the average consensus rating score for medical companies is 2.68. Learn more on how SRPT compares to other companies.
Does Sarepta Therapeutics's stock price have much upside?: According to analysts, Sarepta Therapeutics's stock has a predicted upside of 30.85% based on their 12-month stock forecasts.

What analysts cover Sarepta Therapeutics?: Sarepta Therapeutics has been rated by Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Evercore ISI, Mizuho, Needham & Company LLC, Royal Bank of Canada, UBS Group, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:SRPT) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

SRPT Analyst Ratings By Month

SRPT Price Targets by Month

Sarepta Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

SRPT Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info